COMPANY

Pulmonx

HQ: Redwood City, CA source · pulmonx.com ↗

FDA-cleared device company Past trials only

Pulmonx is a medical-device company in Redwood City, CA that makes the FDA-approved Zephyr Endobronchial Valve, a bronchoscopic treatment for selected patients with severe emphysema. From company website Source · Oct 12, 2026

Keywords: medical devices interventional pulmonology emphysema respiratory Redwood City, CA Pulmonary Emphysema COPD Emphysema or COPD Severe Emphysema Heterogeneous Emphysema Bronchoscopy AeriSeal System Chartis System Zephyr Endobronchial Valve Zephyr Valve Zephyr Valve insertion The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP EBV ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves

Location: Redwood City, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

13Trials (company is sponsor)

Timeline

Mar 4, 2026 Debt Debt financing: $60M (up to, as announced), announced Mar 4, 2026. Source: company release on GlobeNewswire. source ↗
Mar 12, 2024 Trial start —: Zephyr Valve Japan Post-Marketing Surveillance source ↗
Feb 22, 2024 Trial start Not phased (device or behavioral study): An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema source ↗
Jan 4, 2021 Trial start —: Zephyr Etude Post-Inscription (French Registry) source ↗
Dec 15, 2020 Trial start Not phased (device or behavioral study): Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT) source ↗
Jun 4, 2020 Trial start Not phased (device or behavioral study): Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve Insertion source ↗
Feb 5, 2020 Trial start —: Post-Market Clinical Evaluation of the Zephyr Valve 5.5-LP EBV source ↗
Nov 25, 2019 Trial start —: Zephyr Valve Registry (ZEVR) source ↗
2016-11 Trial start Not phased (device or behavioral study): Clinical Investigation of a Modified Staged Treatment Algorithm Using the AeriSeal System source ↗
Jan 28, 2014 Trial start Not phased (device or behavioral study): To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr Valves source ↗
2013-07 Trial start Not phased (device or behavioral study): Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study) source ↗
2012-01 Trial start Not phased (device or behavioral study): A Study of the Use of Chartis System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR) source ↗
2008-05 Trial start Phase 1/Phase 2: Safety and Feasibility Study of the Chartis System With Heterogeneous Emphysema Prior to Endobronchial Lung Volume Reduction (ELVR) source ↗
2008-05 Trial start Phase 1: Safety and Feasibility Study of the Chartis System source ↗

Upcoming milestones

Dec 31, 2026 (ESTIMATED) · · Zephyr Valve Registry (ZEVR) · NCT04186546
Mar 31, 2027 (ESTIMATED) · · Zephyr Valve Japan Post-Marketing Surveillance · NCT06332885
Jun 30, 2027 (ESTIMATED) · Not phased · An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema · NCT06035120

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Debt: $60.0M. Last 2 years.

Mar 4, 2026 Debt financing: $60M (up to, as announced), announced Mar 4, 2026. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 13

Record	Title	Phase	Status	Start	Primary completion
NCT06035120	An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema	Not phased (device or behavioral study)	Recruiting	Feb 22, 2024	Jun 30, 2027 (estimated)
NCT04186546	Zephyr Valve Registry (ZEVR)	Not listed	Active, not recruiting	Nov 25, 2019	Dec 31, 2026 (estimated)
NCT06332885	Zephyr Valve Japan Post-Marketing Surveillance	Not listed	Recruiting	Mar 12, 2024	Mar 31, 2027 (estimated)
NCT04517916	Zephyr Etude Post-Inscription (French Registry)	Not listed	Completed	Jan 4, 2021	Jun 22, 2022 (actual)
NCT04465461	Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve Insertion	Not phased (device or behavioral study)	Completed	Jun 4, 2020	Mar 5, 2024 (actual)
NCT04559464	Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT)	Not phased (device or behavioral study)	Completed	Dec 15, 2020	Oct 24, 2023 (actual)
NCT04161235	Post-Market Clinical Evaluation of the Zephyr Valve 5.5-LP EBV	Not listed	Completed	Feb 5, 2020	Aug 13, 2021 (actual)
NCT01796392	Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)	Not phased (device or behavioral study)	Completed	2013-07	2017-09 (actual)
NCT02022683	To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr Valves	Not phased (device or behavioral study)	Completed	Jan 28, 2014	Jan 20, 2017 (actual)
NCT02877459	Clinical Investigation of a Modified Staged Treatment Algorithm Using the AeriSeal System	Not phased (device or behavioral study)	Completed	2016-11	Nov 16, 2017 (actual)
NCT01101958	A Study of the Use of Chartis System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR)	Not phased (device or behavioral study)	Completed	2012-01	2013-03 (actual)
NCT00684892	Safety and Feasibility Study of the Chartis System With Heterogeneous Emphysema Prior to Endobronchial Lung Volume Reduction (ELVR)	Phase 1/Phase 2	Completed	2008-05	2008-11 (actual)
NCT00684684	Safety and Feasibility Study of the Chartis System	Phase 1	Completed	2008-05	2008-11 (actual)

Connect

See your connections at Pulmonx on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12